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S324 Poster Session IIby progressive localization of the BLI signal to the tumor site. The
accumulation of NK cells increased with increasing tumor size,
such that the BLI signal of NK cells from the tumor bed repre-
sented approximately 30% of the total animal BLI. Survival advan-
tage was not observed in animals receiving NK cells, regardless of
the administration of IL-2. The tumor microenvironment (TME)
contained a network of Treg cells as well as conventional and plas-
macytoid dendritic cells, most of which were donor bone-marrow
derived and were markedly increased when compared with control
tissues (Tregs 40% vs 8%, p5 0.0034; cDC 30% vs 6%, p5 0.02).
Donor NK cells reisolated from the tumor showed a trend to re-
duced activation by CD69 expression (3% compared with 24%
in normal spleen, p5 0.09), and similarly had impaired production
of interferon-gamma upon restimulation.
Conclusions: Adoptively transferred allogeneic NK cells home to
tumor, showing a striking and paradoxical accumulation with in-
creasing tumor size. These NK are de-activated, possibly due to ex-
posure to the immunosuppressive TME.474
SEQUENTIAL GENE EXPRESSION ANALYSIS DURING THE EARLY ALLOR-
EACTIVE PHENOMENA AFTER ALLOGENEIC BMT IDENTIFIES GENE SETS
AND PATHWAYS DIFFERENTIALLY EXPRESSED IN THE SKIN AND THE
BLOOD OF BMT RECIPIENTS: IMPLICATIONS FOR THE DISCOVERY OF
BIOMARKERS OF CUTANEOUS GVHD THAT ARE RELEVANT TO THE
TARGET ORGAN
Duarte,R.F.1,Garcia-Gutierrez, J.V.3, Sanchez-Ortega, I.1,Remigia,M.J.2,
Rodriguez, M.E.4, Pati~no, B.1, Mataix, A.2, Fleta, B.3, Martinez, N.4,
Odriozola, J.3, Solano, C.2, Sanchez-Beato, M.4 1Catalan Institute of Oncol-
ogy, Barcelona, Barcelona, Spain; 2Hospital Clınico Universitario, Valencia,
Valencia, Spain; 3Hospital Ramon y Cajal,Madrid,Madrid, Spain; 4Spanish
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Our understanding of the alloreactive phenomena that follow
allogeneic BMT (alloBMT) and lead to GVHD in target organs
comes essentially from animal models. In humans, the use of tar-
get tissues has been largely limited to diagnostic purposes, while
the study of immunological pathways and biomarkers of GVHD
has been performed in peripheral blood (PB) or urine. Hence,
we decided to collect prospectively and in parallel skin biopsies
and PB samples before and after alloBMT in order to investigate
sequential changes in alloreactive phenomena and biomarkers that
are relevant to the skin as a target organ of GVHD. Sixty-five
adult recipients of alloBMT for hematological malignancies (38
male; age 49, 21-67; 38 reduced intensity; 40 related donor) had
PB and skin biopsies taken pretransplant and on days 0, +14-21,
+100 and at the start of GVHD. A high-throughput discovery-
driven strategy was carried out using Agilent Whole Genome Mi-
croarrays on RNA from PBMCs and snap-frozen skin extracted
with TRIZOL and amplified with RNA ampULSe. Gene expres-
sion data was analyzed using GSEA software (www.broadinstitu
te.org/gsea/index.jsp), GEPAS (www.gepas.org) and POMELO
(http://pomelo2.bioinfo.cnio.es/) web tools. Our initial analysis
presented here focuses on early kinetics of gene expression in
skin and PB after alloBMT. Comparative profiles between pre-
transplant (baseline) and day 0 (post-conditioning) samples iden-
tified different gene sets in PB and in the skin; predominantly
cytokines and their signaling pathways, such as IL2, IL22BP,
IL3, IL4, IL5, IL7, IFNa, EPO, STAT3, ERK5, MAPK, in the
former, and apoptosis, cell cycle and growth (FAS, CDK4,
CDK6, CDKN1B, CDKN2C) in the latter. Gene set enrichment
analysis from day 0 to day +14-21 (engraftment) showed a higher
range of changes in PB (mainly cytokines and immunology gene
sets) than in the skin, which at this point included additional
gene sets from pathways from extracellular matrix and integrins.
This is the first report on a prospective and sequential examina-
tion of gene expression in paired PB and skin samples from
allogeneic BMT recipients. Our results suggest that the pathways
triggered after conditioning therapy and early after BMT differ
between PB and the skin. This finding provides novel insight
into the alloreactive phenomena occurring in humans, and bears
important implications for the identification of novel biomarkers
that may be more relevant to predict GVHD in patients’ target
organs.475
EFFECTIVE TREATMENT OF ACUTE GVHD AFTER HAPLOIDENTICAL BMT
WITH IN VITRO EXPANDED MURINE CD4+CD25+ REGULATORY T CELLS
Boeld, T.J.1, Spacenko, E.1, Eder, R.1, Weber, C.1, Lang-Schwarz, C.2,
Huber, E.2, Andreesen, R.1, Hoffmann, P.1, Edinger, M.1 1University
Hospital, Regensburg, Germany; 2University Hospital, Regensburg,
Germany
Graft-versus-host disease (GvHD) is a major complication after
allogeneic bone marrow transplantation (BMT). We and others
previously showed that the co-transplantation of large numbers of
donor-derived CD4+CD25+ regulatory T (Treg) cells protects
from lethal GvHD inmurine BMTmodels.We now tested, whether
Treg cells have also therapeutic efficacy. For this purpose, a haploi-
dentical GvHDmodel (BALB/c/CB6F1) was used and, in analogy
to potential clinical applications, donor Treg cells were expanded in
vitro. CD4+CD25highCD62L+ T cells were purified by FACS and
stimulated polyclonally using anti-CD3/CD28-coated beads. Cells
expanded on average 140-fold (627-fold, n 5 5) within 2 wks and
maintained high levels of FoxP3 expression (9662.3%, n 5 5) as
well as potent immunosuppressive activity in vitro. For the induction
of acute GvHDCB6F1 recipients were lethally irradiated and trans-
planted with 2.5x106 BM cells in combination with 5x106 spleno-
cytes. All animals developed severe GvHD by d11, as revealed by
an increase of the GvHD severity score (2.360.4 in GvHD animals
vs. 060 in BM controls, n 5 10-11) and by histological analyses of
the gut (score: 7.860.4 GvHD group vs. 0.260.2 BM controls,
p 5 0.046, n 5 3). When animals with acute GvHD were treated
with 5x106 in vitro expanded Treg cells on d11 after BMT, treated
and non-treated animals initially showed an identical increase of
their GvHD score. However, from d40 onwards the GvHD score
of mice that had received Treg cells decreased (4.160.6 vs. 6.060
in treated vs. non-treated mice, respectively, on d44, p 5 0.02) and
60% of these mice survived for 100d while all non-treated animals
died by d60 after BMT (p 5 0.014, n 5 10). Successfully treated
mice showed only mild histological signs of gut GvHD on d100 as
compared to non-treated animals with end-stage disease (score:
4.361 vs. 12.560.6 in treated vs. non-treated animals, p 5 0.006,
n5 4-6).Taken together, these results suggest that in vitro expanded
natural Treg cells may not only be effective for the prevention of
acute GvHD, but also for the treatment of acute gastrointestinal
GvHD after allogeneic BMT.476
A PILOT STUDY OF ONCE-DAILY MODIFIED RELEASE FORMULATION
TACROLIMUS HYDRATE (GRACEPTOR) AND PHARMACOKINETIC
EVALUATION IN UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANT
RECIPIENTS
Yano, S.1, Saito, T.1, Yokoyama, H.1, Machishima, T.1, Yahagi, Y.1,
Sugiyama, K.1, Ogasawara, Y.1, Kasama, K.1, Katsube, A.1, Usui, N.1,
Aiba, K.1, Mori, S.2 1Jikei University School of Medicine, Tokyo, Japan;
2National Cancer Center Hospital, Tokyo, Japan
Background:Graceptor is a once-daily modified release formula-
tion of tacrolimus. Not only it maintains its efficacy at the similar
level with the existing drug, Prograf, but also the once-daily ad-
ministration possibly contributes to reduce physical and mental
stress for patients. We investigated the efficacy and safety of the
once-daily administration of tacrolimus in patients who received
allogeneic hematopoietic stem cell transplant recipients from unre-
lated donors (UD-HSCT).
Methods: Patients received tacrolimus 0.03mg/kg intravenous by
continuous infusion, and administration was converted to oral at
a 1:3 or 4 ratios when the patient could tolerate oral medication.
Doses were modified to maintain whole-blood trough levels of
5-10 ng/ml. To analyze pharmacokinetics (PK) of tacrolimus.
Plasma concentration of tacrolimus was determined by ELISA.
Results: A total of 15 patients with hematological malignancies
(AML 6, ALL 3, MDS 3, CML 1, NHL 2) were enrolled. Median
age was 45 (23-65) years. Preparative regimens were myeloablative
(n5 8) or reduced intensity (n5 7), stem cell sources were bonemar-
row (BM) from HLA-matched unrelated donor (n 5 9), BM from
HLA DRB1 mismatched unrelated donor (n 5 2), or cord blood
(n5 4). Three out of 15 patients (20%) developed grade II-IV acute
GVHD, and 3 of 15 patients (20%) developed chronic GVHD. No
Poster Session II S325patient should discontinue the agent because of adverse effects and
developed treatment related mortality within 100 days after trans-
plantation. PK was completed in 7 patients, and median area-un-
der-curve (AUC) was 246ngh/ml. Although median AUC was
417ngh/ml for the patients who got whole-blood trough over
7ng/ml, median AUC was 177 ngh/ml for the patients trough less
than 6ng/ml.
Conclusions: Because the once-daily modified release formulation
of tacrolimus showed as effective as Prograf, Graceptor might
be able to keep administration for the patients due to reduce stress.
To get enough level of AUC, we should keep whole-blood trough
over 7ng/ml. These findings indicate that the use of Graceptor in-
stead of Prograf for GVHD prophylaxis is beneficial for patients
undergoing UD-HSCT.477
TELOMERASE ACTIVITY IN REGULATORY T CELLS IS INVERSELY ASSOCI-
ATED WITH SEVERITY OF CHRONIC GRAFT-VERSUS-HOST DISEASE
(CGVHD) AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
(HSCT)
Kawano, Y., Kim, H.T., Matsuoka, K.-I., Smith, R., Lazo-Kallanian, S.,
Daley, J., Ho, V.T., Cutler, C., Koreth, J., Alyea, E.P., Antin, J.H.,
Soiffer, R.J., Ritz, J. Dana-Farber Cancer Institute, Boston, MA
CD4+CD25+Foxp3+ regulatory T cells (Treg) play an important
role in the maintenance of peripheral tolerance and control of
chronic graft versus host disease (cGVHD). Previous studies have
shown that Treg undergo extensive homeostatic proliferation after
allogeneic HSCT. However, Treg are also susceptible to apoptosis,
and the inability to maintain survival of rapidly proliferating Treg
may contribute to the development of cGVHD. Telomeres play an
important role in cell senescence and we examined whether telome-
rase activity and telomere length were associated with Treg homeo-
stasis after allogeneic HSCT and cGVHD. We examined Treg and
conventional CD4 T cells (Tcon) in 52 patients with hematologic
malignancies who survived more than 2 years after HSCT. Tcon
and Treg were purified by flow cytometric cell sorting. Relative telo-
mere length was measured by real time PCR. Telomerase activity
was measured by PCR-ELISA. Telomere length was significantly
shorter in Treg compared to Tcon in all patients (0.10 vs 0.25;
p\0.0001), but Treg telomere length was not correlated with sever-
ity of cGVHD. Treg telomerase activity and Treg number were
inversely associated with severity of cGVHD (Treg telomerase activ-
ity/Treg cell number/ul, 37/33 in no cGVHD, 34/20 in mild
cGVHD, 7/19 in moderate cGVHD, 1.2/8 in severe cGVHD; p\
0.0001, p 5 0.01, respectively). Ki-67 expression, a measure of pro-
liferation, was higher in Treg compared with Tcon in all patients
(5.7% vs 0.9%; p\0.0001), and Ki-67 in Treg was inversely associ-
ated with severity of cGVHD (p 5 0.002). Bcl-2 expression, a mea-
sure of susceptibility to apoptosis, in Treg was also inversely
associated with severity of cGVHD (p 5 0.0009). Finally, there
was a significant correlation between Treg telomerase activity and
Bcl-2 expression (r5 0.69, p\0.0001), suggesting that high telome-
rase activity is associated with other mechanisms that promote
survival of Treg. These data indicate that activation of telomerase
in Treg after allogeneic HSCT does not prevent overall telomere
shortening. However, telomerase activation increases the replicative
life span of Treg by protecting them from apoptosis. Failure to acti-
vate telomerase in Treg restricts their proliferative capacity and also
appears to increase apoptotic susceptibility, resulting in the loss of
peripheral tolerance and the development of severe cGVHD.478
HIGH IL-15 SERUM LEVELS ON DAY 7 AFTER HEMATOPOIETIC CELL
TRANSPLANTATION ARE ASSOCIATED WITH A LOW LIKELIHOOD OF
GVHD AND A HIGH LIKELIHOOD OF INFECTIONS
Hagel, L., Liu, Y., Ugarte-Torres, A., Hoegh-Petersen, M.,
Williamson, T.S., Russell, J.A., Storek, J. University of Calgary, Calgary,
AB, Canada
Background:Hematopoietic cell transplantation (HCT) is typically
curative for hematologic malignancies. Unfortunately, success of
HCT is limited by side effects, primarily graft-vs-host disease(GVHD) and infections. As preemptive therapy of GVHD or infec-
tions would likely be efficacious if started early posttransplant, we set
out to determine whether the levels of IL-15 on day 7 are associated
with subsequent development of GVHD or infections.
Patients and Methods: In 158 allogeneic transplant recipients we
determined serum IL-15 levels using sandwich ELISA (R&D). IL-
15 levels in patients with versus without aGVHD (grade 2-4),
cGVHD (needing systemic therapy) or relapse were compared using
Mann-Whitney-Wilcoxon test, and correlation with infection rates
were evaluated using Spearman rank correlation test. Multivariate
analyses were performed adjusting for recipient age, donor type,
donor/recipient sex, stem cell source and, for relapse, also disease/
disease stage and, for infections, also engraftment day and aGVHD
or cGVHD.
Results: In univariate analyses IL-15 levels were significantly associ-
ated with aGvHD and cGvHD (median 29 vs 40 pg/mL in patients
with vs without aGVHD, p5 .02, and median 25 vs 40 pg/mL in pa-
tients with vs without cGVHD, p5 .02). IL-15 levels were similar in
patients who did vs did not develop relapse (30 vs 39 pg/mL, p 5
0.60). There was a positive correlation between IL-15 levels and
the rates of definite (microbiologically documented) infections
(p5 .008), total (definite or presumed) infections (p5 .008), viral in-
fections (p5 .06), bacterial infections (p5 .06) and fungal infections
(p5 0.03) occurring between day 7 and 83. In multivariate analyses,
IL-15 levels above 31.0 pg/mL were associated with a 0.38-fold risk
of aGVHD (p 5 0.005), and levels above 31.3 pg/mL with a 0.35-
fold risk of cGVHD (p\ .008). For a unit increase of IL-15 level
(change of 1 pg/mL), the rate of infections increased 1.02-fold
(p\ .001) for definite infections, 1.03-fold for total infections (p\
.001), 1.03-fold for viral infections (p\ .001), 1.02-fold for bacterial
infections (p\ .001) and 1.03-fold for fungal infections (p 5 .06).
Conclusion:High IL-15 levels were associated with a low likelihood
of GVHD and a high likelihood of infections, including viral, bacte-
rial and fungal infections. Thismay reflect the fact that themost lym-
phopenic patients may have had the highest levels of IL-15,
a homeostatic growth factor for CD8 T cells and NK cells.479
PREDICTIVE VALUE OF SCORING SYSTEM WITH AUTOANTIBODY
EXPRESSIONS IN ALLOGENEIC STEM CELL RECIPIENTS
Sohn, S.K.1, Moon, J.H.1, Do, Y.R.2, Lee, S.J.1, Kang, B.W.1,
Chae, Y.S.1, Kim, J.G.1 1Kyungpook National University Hospital,
Daegu, Korea; 2Keimyung University Dongsan Medical Cente, Daegu,
Korea
Background: In our previous study, patients expressing autoanti-
bodies especially ANA showed a better survival in allogeneic stem
cell recipients. The current study was designed to implicate the ex-
pression of autoantibodies as an prognostic marker after allogeneic
stem cell transplantation (SCT).
Methods:A total of 144 consecutive patients who underwent alloge-
neic SCT from November 2001 to Sep 2009 and survived at least 3
months were included in the current study. ANA and anti-dsDNA
were screened at 3, 6, 12 month and yearly thereafter.
Results:ANAwas positive in 31 patients (21.5%) at median 364 days
(range, 90-1141) and anti-dsDNA (. 3.0 IU/mL) in 76 (52.8%) at
median 100 days (range, 46-1458). In the multivariate analysis,
ANA [hazard ratio (HR) 0.315] and anti-dsDNA . 3.0 IU/mL
(HR 0.328) were identified as good prognostic factors for survival
and relapse. When scored as the number of autoantibody expression
with ANA and anti-dsDNA; score 0 as no autoantibody expression,
score 1 as one and score 2 as two, the patients for score 2 showed
a 91.8% 5-yr overall survival (OS) (HR 0.075, p \ 0.001) and
0.4% relapse rate (HR 0.059, p \ 0.006), those for score 1
a 64.1% 5-yr OS (HR 0.352, p \ 0.001) and 26.3% relapse rate
(HR 0.422, p 5 0.011), and those for score 0 a 35.7% 5-yr OS and
53.7% relapse rate.
Conclusion: Patients expressing multiple autoantibodies (ANA and
anti-dsDNA) showed a better survival and lower relapse rate in allo-
geneic stem cell transplantation settings. Scoring with autoantibody
expressions could be used as a prognostic marker for long-term
survival and lower relapse risk after allogeneic SCT.
